Aptevo Therapeutics (NASDAQ:APVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report report published on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm dropped their price target on Aptevo Therapeutics from $20,535.00 to $10,952.00 and set a “buy” rating for the company in a research report on Monday, September 23rd.

Aptevo Therapeutics Trading Up 8.8 %

APVO stock opened at $10.01 on Monday. Aptevo Therapeutics has a 12-month low of $5.11 and a 12-month high of $399.60. The business’s 50-day moving average is $293.51 and its 200 day moving average is $485.86.

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.